Report: District court denies preliminary injunction, upholding Maryland law protecting 340B pricing for contract pharmacy arrangements
![court-900x400](/sites/default/files/styles/900x400/public/2018-01/court-900x400.png?itok=s8D2_ej1)
A district court in Baltimore Sept. 5 ruled against drug companies and PhRMA, denying their attempt to obtain a preliminary injunction against 340B pricing for contract pharmacy arrangements in Maryland, according to Reuters. The AHA filed amicus briefs defending Maryland’s law against this drug industry challenge July 29 and Aug. 2, in addition to similar briefs filed in Missouri Aug. 29 and West Virginia Aug. 16.
Related News Articles
Headline
The AHA Sept. 9 released a report highlighting how hospitals’ arrangements with community and specialty pharmacies improve access to care for underserved…
Headline
The AHA, 340B Health and the American Society of Health-System Pharmacists last week filed an amicus brief in a federal district court in Missouri, defending…
Headline
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the…
Headline
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the…
Headline
Johnson & Johnson announced Aug. 23 that it would be fundamentally changing the way it makes 340B pricing available for two of its most popular products,…
Headline
A Texas federal court Aug. 20 ruled set aside the Federal Trade Commission’s Non-Compete Clause Final Rule. U.S. District Judge Ada Brown held the FTC lacked…